BAT1706

DRUG3 trials

Sponsors

Bio-Thera Solutions, BeOne Medicines, BeiGene

Conditions

Advanced Hepatocellular CarcinomaAdvanced MalignanciesNon-squamous Non-small Cell Lung Cancer

Phase 2

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

CompletedNCT04948697

BeiGeneAdvanced Hepatocellular Carcinoma

Start: 2021-08-20End: 2024-02-01Updated: 2025-02-24

Phase 3

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

CompletedNCT03329911

Bio-Thera SolutionsNon-squamous Non-small Cell Lung Cancer

Start: 2017-10-20End: 2021-05-27Updated: 2021-09-14

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Active, not recruitingNCT04164199

BeOne MedicinesAdvanced Malignancies

Start: 2019-12-19End: 2026-07-01Updated: 2026-03-27

Related Papers

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.

2023-07-2010 citations

Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

Journal of Clinical Oncology2022-06-013 citations

AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2022-06-013 citations

AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2022-01-191 citations

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Clinical Cancer Research2021-10-2944 citations